Short Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 9.6%

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) saw a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 6,220,000 shares, a decrease of 9.6% from the November 15th total of 6,880,000 shares. Based on an average daily volume of 1,260,000 shares, the short-interest ratio is currently 4.9 days.

Insider Buying and Selling

In related news, Director Jeffrey Allen Bailey sold 4,557 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $8.43, for a total transaction of $38,415.51. Following the sale, the director now directly owns 13,356 shares of the company’s stock, valued at approximately $112,591.08. This represents a 25.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AUPH. State Street Corp lifted its holdings in Aurinia Pharmaceuticals by 2.3% during the third quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock worth $21,587,000 after buying an additional 64,949 shares during the period. Vanguard Group Inc. increased its holdings in Aurinia Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 1,531,617 shares of the biotechnology company’s stock worth $7,673,000 after buying an additional 21,119 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Aurinia Pharmaceuticals by 13.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock worth $5,454,000 after acquiring an additional 89,940 shares during the period. Segall Bryant & Hamill LLC raised its stake in shares of Aurinia Pharmaceuticals by 1.6% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 562,775 shares of the biotechnology company’s stock valued at $4,125,000 after buying an additional 9,031 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in Aurinia Pharmaceuticals by 4,307.9% during the third quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock valued at $4,015,000 after acquiring an additional 535,301 shares in the last quarter. 36.83% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

AUPH has been the topic of several research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. Finally, StockNews.com cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Trading Down 1.5 %

AUPH stock traded down $0.14 during midday trading on Tuesday, reaching $9.49. 89,314 shares of the company traded hands, compared to its average volume of 1,598,417. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -64.20 and a beta of 1.41. The business has a 50 day moving average of $8.09 and a 200-day moving average of $6.79. Aurinia Pharmaceuticals has a 52-week low of $4.71 and a 52-week high of $10.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.